Here are the S-1 registration statements from Syra Health Corp A (SYRA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow SYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYRA filings page.
Syra Health Corp (SYRA) has filed a Form S-1 registering for resale up to 3,171,100 shares of Class A common stock issuable upon exercise of its Series B warrants. The warrants, issued in a September 2024 registered direct offering, are exercisable at $0.64 per share until September 13, 2029. Syra will not receive proceeds from selling stockholders’ resales but would receive up to about $2.03 million in gross cash proceeds if all such warrants are exercised for cash.
Syra is a healthcare services company focused on behavioral and mental health (including its Syrenity app launched in late 2024), population health analytics, digital health platforms, health education, and healthcare workforce staffing. Revenue was $8.0 million in 2024, $7.2 million in 2025, and $4.7 million for the six months ended June 30, 2026.
The company reported net losses of $3.76 million in 2024 and $0.90 million in 2025, but net income of $0.49 million for the first half of 2026, with an accumulated deficit of $9.23 million and cash of $2.12 million as of June 30, 2026. Its auditor raised substantial doubt about its ability to continue as a going concern, and management expects existing cash and cash from operations will not fund operations for 12 months without additional capital. Syra is an emerging growth and smaller reporting company, trades on the OTCQB, and highlights significant customer concentration and extensive healthcare regulatory and government contracting risks.